Announced Date: 2023-02-12 (February 12, 2023)
Asset Name: SHR2554 (TLN-254)
Licensor: Hengrui Pharmaceuticals Co. Ltd (China)
Licensee (Buyer): Treeline Biosciences, Inc. (US）
.
Asset Modality: Small Molecule
Asset Target: EZH2 inhibitor (Enhancer of Zeste Homolog 2)
Potential Indication: lymphoma
Current Stage: Phase I, China
.
Scope of Authority:
Treeline will be granted worldwide exclusive rights to the EZH2 inhibitor SHR2554, except for greater China (Mainland China, Hong Kong, Macau and Taiwan).
.
Deal Detail:
Upfront payment of $11 million,
Development and regulatory milestone payments up to $45 million,
Sales milestone payments up to $650 million,
Total up to $706 million.
Royalties on net sales, tiered (10%-12.5%).
.
Link:
